Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue				5K -
gross profit				-5K -
selling and marketing expenses				-5K -
general and administrative expenses	9.77M -	8.06M 17.43%	10.16M 25.98%	13.01M 28.02%
selling general and administrative expenses	9.77M -	8.06M 17.43%	10.16M 25.98%	13.00M 27.97%
research and development expenses	4.63M -	19.77M 326.81%	34.64M 75.17%	43.75M 26.31%
other expenses		-22K -	16K 172.73%
cost and expenses	14.40M -	27.84M 93.33%	44.80M 60.92%	56.76M 26.70%
operating expenses	14.40M -	27.84M 93.33%	44.80M 60.92%	56.75M 26.69%
interest expense			837K -
ebitda	-14.40M -	-27.84M 93.32%	-44.80M 60.92%	-56.75M 26.69%
operating income	-14.40M -	-27.84M 93.33%	-44.80M 60.92%	-56.76M 26.70%
depreciation and amortization		1K -	5K 400%	5K 0%
total other income expenses net		42K -	853K 1,930.95%	2.34M 173.97%
income before tax	-14.40M -	-27.80M 93.03%	-43.95M 58.09%	-54.42M 23.84%
income tax expense		-64K -	-853K 1,232.81%
net income	-14.40M -	-27.73M 92.59%	-43.09M 55.38%	-54.42M 26.29%
weighted average shs out	16.92M -	14.41M 14.82%	17.15M 19.02%	22.73M 32.51%
weighted average shs out dil	16.92M -	14.41M 14.82%	17.15M 19.02%	22.73M 32.51%
eps	-0.85 -	-1.92 125.88%	-2.51 30.73%	-2.39 4.78%
epsdiluted	-0.85 -	-1.92 125.88%	-2.51 30.73%	-2.39 4.78%

COM:LONGBOARDPHARMA

Longboard Pharmaceuticals

Last Close

59.77

22/11 21:00

Market Cap

1.44B

Beta: -

Volume Today

1.29M

Avg: -

Preview